These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38583976)

  • 1. [The persistence and the reasons for discontinuation of daily teriparatide self-injection (dTPTD); difference between inpatients and outpatients when started dTPTD].
    Nihon Ronen Igakkai Zasshi; 2024; 61(1):87-89. PubMed ID: 38583976
    [No Abstract]   [Full Text] [Related]  

  • 2. Persistence with teriparatide in patients with osteoporosis: the UK experience.
    Arden NK; Earl S; Fisher DJ; Cooper C; Carruthers S; Goater M
    Osteoporos Int; 2006; 17(11):1626-9. PubMed ID: 16823543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistence of and switches from teriparatide treatment among women and men with osteoporosis in the real world: a claims database analysis.
    Usui T; Funagoshi M; Seto K; Ide K; Tanaka S; Kawakami K
    Arch Osteoporos; 2018 May; 13(1):54. PubMed ID: 29725863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of a patient-support program on once-daily teriparatide adherence and persistence in the Japan Fracture Observational Study (JFOS).
    Sato M; Tsujimoto M; Kajimoto K; Uetake H; Shimoda H; Fujiwara S
    Arch Osteoporos; 2018 Jul; 13(1):74. PubMed ID: 29978364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in persistency with teriparatide in patients with osteoporosis according to gender and health care provider.
    Kyvernitakis I; Kostev K; Kurth A; Albert US; Hadji P
    Osteoporos Int; 2014 Dec; 25(12):2721-8. PubMed ID: 25011986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two-year persistence with teriparatide improved significantly after introduction of an educational and motivational support program.
    van Maren MA; Wyers CE; Driessen JHM; Visser JV; de Vries F; van de Wijdeven K; Gevers S; Lems WF; Emmelot-Vonk MH; van den Bergh JPW
    Osteoporos Int; 2019 Sep; 30(9):1837-1844. PubMed ID: 31321446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of a phone follow-up program on persistence with teriparatide or PTH(1-84) treatment.
    Tamone C; Fonte G; Panico A; Molinatti PA; D'Amelio P; Isaia GC
    Calcif Tissue Int; 2012 Apr; 90(4):272-8. PubMed ID: 22322409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
    Adachi JD; Hanley DA; Lorraine JK; Yu M
    Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of Teriparatide and Sequential Antiresorptive Agent Treatment Among Elderly Female Medicare Beneficiaries.
    Liu J; Laster A; Xu X; Guo H; Oates M; Gandra SR
    J Bone Miner Res; 2021 Dec; 36(12):2309-2316. PubMed ID: 34490946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors for self-discontinuation of anti-osteoporosis medication: A hospital-based real-world study.
    Deng YL; Hsu CS; Hsu CY; Chen CH; Ou SF; Liu CF; Yang SH; Shih CH; Chen YM; Lee HT
    PLoS One; 2022; 17(9):e0275020. PubMed ID: 36129951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy.
    Kaufman JM; Orwoll E; Goemaere S; San Martin J; Hossain A; Dalsky GP; Lindsay R; Mitlak BH
    Osteoporos Int; 2005 May; 16(5):510-6. PubMed ID: 15322742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Daily subcutaneous injection of teriparatide : the progress and current issues].
    Yano S; Sugimoto T
    Clin Calcium; 2014 Jan; 24(1):35-43. PubMed ID: 24369278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter, randomized, rater-blinded, parallel-group, phase 3 study to compare the efficacy, safety, and immunogenicity of biosimilar RGB-10 and reference once-daily teriparatide in patients with osteoporosis.
    Hagino H; Narita R; Yokoyama Y; Watanabe M; Tomomitsu M
    Osteoporos Int; 2019 Oct; 30(10):2027-2037. PubMed ID: 31243480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world effectiveness of daily teriparatide in Japanese patients with osteoporosis at high risk for fracture: final results from the 24-month Japan Fracture Observational Study (JFOS).
    Soen S; Fujiwara S; Takayanagi R; Kajimoto K; Tsujimoto M; Kimura S; Sato M; Krege JH; Enomoto H
    Curr Med Res Opin; 2017 Nov; 33(11):2049-2056. PubMed ID: 28699789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of an educational support program to assist patients receiving injectable osteoporosis treatment: experience with teriparatide.
    Nogues X; Luz Rentero M; Rodríguez AL
    Curr Med Res Opin; 2014 Feb; 30(2):287-96. PubMed ID: 24102317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years.
    Modi A; Sajjan S; Insinga R; Weaver J; Lewiecki EM; Harris ST
    Osteoporos Int; 2017 Apr; 28(4):1355-1363. PubMed ID: 28058444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience.
    Briot K; Ravaud P; Dargent-Molina P; Zylberman M; Liu-Leage S; Roux C
    Osteoporos Int; 2009 Apr; 20(4):625-30. PubMed ID: 18661089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world persistence of twice-weekly teriparatide and factors associated with the discontinuation in patients with osteoporosis.
    Fujita R; Endo T; Takahata M; Haraya K; Suzuki H; Oda I; Kanayama M; Asano T; Shigenobu K; Iwata A; Yamada K; Takeuchi H; Ohura H; Yoneoka D; Iwasaki N
    J Bone Miner Metab; 2022 Sep; 40(5):782-789. PubMed ID: 35759143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Teriparatide persistence and tolerance in patients with osteoporosis: Observational data from clinical practice.
    Taisne N; Mignot MA; Legroux I; Cortet B; Paccou J
    Joint Bone Spine; 2018 Oct; 85(5):641-642. PubMed ID: 29407040
    [No Abstract]   [Full Text] [Related]  

  • 20. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment.
    Prince R; Sipos A; Hossain A; Syversen U; Ish-Shalom S; Marcinowska E; Halse J; Lindsay R; Dalsky GP; Mitlak BH
    J Bone Miner Res; 2005 Sep; 20(9):1507-13. PubMed ID: 16059622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.